Bunondol

Buprenorphine

Method of action: Analgesic, Analgesic (Opioid), Other Nervous System Drugs

Treatment option: Pain, Drug Addiction, Cancer, Angina Pectoris

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bunondol

Bunondol is a powerful prescription-only medication whose active component is Buprenorphine. It is primarily classified as a semi-synthetic opioid analgesic, functioning through its interaction with pain receptors in the central nervous system. This foundational section addresses the medication's identity, composition, and general purpose.

Quick Facts

Property	Description
Active ingredient	Buprenorphine
Form	Tablet, often sublingual
Pharmacological class	Partial opioid agonist
General purpose	Relief of moderate to severe pain
Origin	Semi-synthetic

What is Bunondol and Its Primary Classification?

Bunondol is defined as a potent, semi-synthetic opioid analgesic medication, identified by its single active ingredient, Buprenorphine. This highly potent compound belongs to the pharmacological class of partial opioid agonists, which distinguishes its fundamental mode of action from traditional, full opioid agonists such as Morphine. The designation as an opioid analgesic confirms its central role in pain management by acting on the central nervous system. The term partial opioid agonist is essential, as it indicates the drug provides powerful pain relief while exhibiting a ceiling effect on receptor activation. Buprenorphine functions through a unique dual mechanism as an opioid receptor modulator. Buprenorphine’s binding profile helps to manage pain effectively while reducing the risk of full agonism, a property recognized for its potential benefit in complex pain management strategies.

Composition, Origin, and Pharmaceutical Form

The core of Bunondol is the semi-synthetic compound Buprenorphine, typically formulated as a single-ingredient product contained within a tablet. Although manufactured in different presentations, the most recognized dosage form is the sublingual tablet, which utilizes the sublingual route of administration. This method, involving placement under the tongue, is crucial because it facilitates the rapid and efficient absorption of Buprenorphine directly into the bloodstream, bypassing the digestive system's degradation processes. Sublingual administration is necessary for optimal absorption. This method ensures the active medicine quickly reaches the system to start working, a differentiating factor that highlights its unique delivery.

The General Purpose of Buprenorphine

The general purpose of this medication is to provide effective, sustained relief for moderate to severe pain that is not adequately managed by less potent non-opioid options. As a potent partial opioid agonist, Buprenorphine's ability to bind tightly to pain receptors establishes it as a highly specialized and powerful agent for reducing the overall intensity of chronic or acute pain sensations. This therapeutic role makes it an important component within the broader scope of comprehensive pain management, such as addressing persistent pain after surgical procedures.

Regulatory References

What side effects are possible with Bunondol?

Possible Side Effects and Safety Information

Bunondol, whose active component is Buprenorphine, has a formally defined safety profile that includes serious warnings and common adverse reactions, as documented by regulatory agencies worldwide.

Serious Safety Risks and Contraindications

The medicine is associated with mandatory warnings concerning life-threatening respiratory depression, with the risk being greatest during the initiation of therapy or following a dose increase. The label also explicitly documents the risk of addiction, abuse, and misuse inherent to the opioid class of medications. The concomitant use of Buprenorphine with CNS depressants (e.g., benzodiazepines) is a major restriction due to the potential for profound sedation, coma, and death.

Buprenorphine is contraindicated in patients with pre-existing conditions such as significant respiratory depression, acute or severe asthma, and severe hepatic insufficiency.

Common Adverse Reactions and Affected Systems

Adverse events classified as common in official regulatory documents (incidence 5%) typically involve the Gastrointestinal and Nervous Systems. Commonly reported reactions include headache, nausea, vomiting, and constipation. Other common effects include dizziness, somnolence (drowsiness), insomnia, and hyperhidrosis (sweating).

Local effects related to the sublingual tablet form, such as oral hypoesthesia (numbness) and glossodynia (tongue pain), are also commonly documented.

Population and Exposure-Related Notes

The label specifies that prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome (NOWS). Additionally, the drug may precipitate opioid withdrawal signs if administered to a physically dependent individual before the full opioid effects have subsided. Caution is advised for geriatric patients, who require close monitoring for sedation and respiratory depression.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Bunondol (Buprenorphine) is defined by its potential for severe and life-threatening manifestations. The most critical documented sign of overdose is respiratory depression, which may lead to fatal outcomes. Overdose often presents with profound Central Nervous System (CNS) depression, including stupor, coma, and severe sedation, along with cardiovascular signs such as hypotension. Changes in pupil size, ranging from miosis (pinpoint pupils) to mydriasis (dilation) due to low oxygen, are also noted.

Immediate medical attention is required when signs of severe CNS impairment, such as inability to wake up, or any respiratory compromise are observed. Regulatory information mandates that individuals contact emergency services immediately in these situations or following accidental ingestion by any person, particularly a child. The risk of overdose is heightened when Buprenorphine is taken with other CNS depressants, such as alcohol or benzodiazepines.

Overdose management involves symptomatic and supportive treatment. Although the opioid antagonist Naloxone is the designated reversal agent, official documentation specifies that higher and repeated doses of Naloxone may be necessary due to Buprenorphine's long duration of action. Furthermore, patients with hepatic impairment are identified as a population with increased risk for toxicity and overdose.

Therapeutic Uses of Bunondol

What Bunondol Treats: Main Uses and Benefits

Quick Fact: Symptomatic Support for Persistent Pain

Property	Description
Symptom Type	High-intensity, persistent, recurrent discomfort
Severity Range	Moderate to severe
Common Scenarios	Postoperative, post-traumatic, malignant pain

The primary therapeutic role of Bunondol (Buprenorphine) is to offer symptomatic relief for pain in situations involving significant and persistent discomfort. The medication is generally used to relieve severe and persistent pain that is expected to require continuous support and has not been adequately addressed by less potent options. The therapeutic use is relevant for easing symptoms that interfere with daily functioning and create noticeable physiological strain.

Bunondol is considered relevant for easing the burden of high-intensity and persistent, recurrent discomfort that typically falls within the moderate to severe range. It is commonly used to help with conditions characterized by periods of heightened symptoms, supportive relief in acute clinical contexts like postoperative pain and post-traumatic pain, and addressing pain associated with malignant disease. The medication may assist with managing these pronounced symptomatic manifestations, and supports general well-being during symptomatic phases for chronic pain patients. This analgesic support is commonly used when supportive symptom management is appropriate, and may assist with maintaining functional stability during phases of increased distress or discomfort.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope: Official Regulatory Information

The eligibility profile for Bunondol (Buprenorphine) is strictly defined by regulatory authorities based on a patient's clinical state, age, and organ function. Use is primarily established for adults (18+ years).

Eligibility Status	Population or Condition
Contraindicated	Documented allergy to Buprenorphine or components.
Contraindicated	Patients with severe respiratory insufficiency.
Contraindicated	Individuals with severe hepatic insufficiency (Severe liver impairment).
Contraindicated	Patients with acute alcoholism or delirium tremens.

Age-Related Rules

The safety and effectiveness of Bunondol have not been established for use in the pediatric population (children under 16 years of age). For the geriatric population, caution and close monitoring are required due to the increased likelihood of diminished organ function.

Condition-Specific Restrictions

Organ Impairment: Patients with moderate hepatic impairment or severe renal impairment require caution and potentially dose adjustment, as stated in official labeling.
Opioid Exposure: The product is not appropriate as an analgesic in opioid-naïve individuals due to the risk of severe respiratory depression. It must also not be administered to patients currently dependent on full opioid agonists until the agonist effects have subsided, to prevent precipitated withdrawal.

Pregnancy and Lactation Eligibility

Use during pregnancy is not indicated unless the potential benefit justifies the potential risk; prolonged use is associated with the expected risk of Neonatal Opioid Withdrawal Syndrome (NOWS). Breastfeeding is not advised while taking the medicine, as Buprenorphine passes into mother's milk.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Bunondol

Interaction scope

Medicinal product categories with documented interactions: Central Nervous System (CNS) Depressants, Serotonergic Drugs, CYP3A4 Inhibitors, CYP3A4 Inducers, and full Opioid Agonists.
Specific interacting medicines (if explicitly listed): Alcohol, Methadone, Naltrexone, and certain Anticonvulsants (e.g., Carbamazepine) or Antifungals (e.g., Ketoconazole).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic reinforcement (additive depressant/serotonergic effect) and Pharmacokinetic clearance alteration via the CYP3A4 enzyme system.
Timing-based interaction rules (if applicable): Administration must be delayed until objective signs of withdrawal are present after the use of a full opioid agonist (typically six hours after a short-acting opioid or twenty-four hours after Methadone).
Population-specific interaction notes (if applicable): Use is contraindicated in patients with severe hepatic impairment and may not be appropriate for those with moderate impairment.
Interaction-related restrictions: Co-administration with Alcohol and Naltrexone is restricted due to severe risk classifications.

Interaction Classifications (high-level)

Interaction severity classification (as defined in official documents): Combinations are classified as Contraindicated (e.g., Naltrexone) or bearing Serious, Life-Threatening Risk (e.g., CNS Depressants).
Interaction-context constraints (as defined in official documents): Initiation of treatment with CYP3A4 inhibitors or inducers requires specific monitoring to evaluate potential over- or under-dosing.

Resulting interaction structure

Official interaction statements: Concomitant use with CNS Depressants may result in profound sedation and respiratory depression. Co-administration with CYP3A4 inhibitors may increase Bunondol exposure, while inducers may decrease exposure.
Connection to the overall interaction profile (2–4 sentences): Regulatory documentation defines the product's interaction structure primarily through constraints on additive CNS depressant effects and modifications to metabolic clearance. These constraints establish mandatory timing separation requirements for opioid rotation and restrict use in specific populations due to clearance considerations.

Mechanism of Action

Partial Mu-Opioid Receptor Agonism

Bunondol contains buprenorphine, a substance that engages a complex binding and signaling profile at opioid receptors within the central nervous system. Its primary action is as a partial agonist at the mu-opioid peptide (MOP) receptor. Partial agonism means it activates the receptor but only produces a submaximal response, resulting in submaximal intrinsic activity at the receptor site. This partial agonism modulates downstream G-protein signaling to a defined level.

High-Affinity Receptor Binding

Bunondol exhibits a high affinity for the MOP receptor, which mediates strong and rapid binding. Furthermore, its slow dissociation kinetics prolong the occupancy of the MOP receptor, resulting in sustained receptor modulation within the targeted signaling cascades and driving persistent molecular changes in pathway activity.

Kappa-Opioid Receptor Antagonism

The drug also functions as an antagonist at the kappa-opioid peptide (KOP) receptor. By acting as a KOP receptor antagonist, it inhibits receptor-mediated signaling. This antagonistic action modifies signaling pathways that influence emotional and stress-related neurological activity, creating a composite pattern of MOP/KOP receptor activity that modulates afferent signaling.

Dosage and Administration Information

Official Administration Guidelines

Bunondol (Buprenorphine) is officially administered via the sublingual route, which involves placing the tablet under the tongue. This method is essential because the medication is rendered ineffective if swallowed, due to poor absorption via the digestive system. The tablet must be held under the tongue until completely dissolved, a process that typically requires five to ten minutes, and must not be chewed, cut, or swallowed. Patients are instructed not to eat or drink anything until the tablet has fully dissolved.

Treatment is initiated in an Induction Phase under clinical supervision. The first dose must be administered only when objective signs of opioid withdrawal are evident, generally four to six hours after the last short-acting opioid use. Following induction, the regimen shifts to a Maintenance Phase, typically consisting of a single daily dose. Maintenance dosages generally range from 4 mg to 24 mg buprenorphine per day, with the final amount determined by individual response. Treatment is generally intended for adults and adolescents over 15 years of age. When the treatment is concluded, the official instructions require the dosage to be gradually tapered to mitigate potential withdrawal symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bunondol

Evidence for Use in Acute Pain Management

Research for Bunondol (Buprenorphine) has explored its use in acute pain settings—such as after a surgical procedure or a serious injury—and has primarily relied on short-term, randomized controlled trials (RCTs). These studies were used in research exploring how outcomes related to physical discomfort change over time. Researchers designed these trials to monitor measurements of change in pain intensity over time and the duration of observed effects. Research also explored whether the need for other supplemental pain medication was different between study populations.

The findings from these studies describe patterns observed in the study populations over defined time intervals, usually lasting hours up to a few days. The research focused heavily on outcomes related to monitoring acute changes in patient-reported outcomes describing perceived discomfort. These research efforts help contextualize how patients reported their experience during periods of increased symptom activity immediately following the acute event.

Evidence for Use in Persistent Chronic Pain

Bunondol was also evaluated in studies examining patient-reported experiences in conditions characterized by persistent, moderate to severe chronic pain. For this purpose, researchers have conducted intermediate-term RCTs (typically lasting several months) and longer-term observational studies and registry analyses. Research examined outcomes related to systemic or functional imbalance over extended periods in patients with conditions characterized by functional limitations and symptoms that may vary in intensity.

The research describes findings related to changes measured during the study period for both pain intensity and outcomes reflecting daily functioning or activity level. Findings were mixed when research examined the relationship between patient-reported discomfort and changes in general daily activity. Studies report how symptoms evolved in the observed populations, helping to contextualize pain management strategies.

Areas of Research Uncertainty and Study Limitations

Studies exploring responses in specific groups, such as older adults, patients with pre-existing organ impairment, or adolescents, have limited evidence available. Consequently, generalizability is limited to the populations studied, and data for certain groups, such as those defined by specific coexisting medical conditions, remain insufficient. Furthermore, follow-up durations were modest in the most controlled trials, and there is limited information for long-term outcomes. Comparative evidence against all alternative pain treatments is lacking in some areas, leaving some subgroup findings uncertain.

Key Studies & References Public Assessment Report Scientific discussion Norspan 5, 10 and 20 micg/h transdermal patches Buprenorphine (EMA/National document on transdermal formulation)

Frequently Asked Questions (FAQ)

Common questions about Bunondol (FAQ)

Q: Is Bunondol used for the same conditions as other similar drugs?

According to official prescribing information, Bunondol's primary use is to provide relief for moderate to severe pain. In addition, the active ingredient in Bunondol is also indicated for the treatment of opioid dependence in certain regulatory contexts. This dual-use classification is typical for this type of medication.

Q: How long should I expect Bunondol to take before its effect is noticeable?

Official documents indicate that after the sublingual tablet has dissolved, the onset of pain relief is typically noticeable within 30 minutes to one hour. The sublingual route of administration facilitates the rapid absorption of the active medicine into the system.

Q: How long does the effect of a single dose of Bunondol typically last?

Based on pharmacokinetic data in the official product information, the analgesic effect of a single dose may last for approximately six to eight hours. This duration of action is generally relevant to the established frequency of use described in official documents.

Q: Are there any major side effects of Bunondol that are often overlooked by patients?

Regulatory documents emphasize several serious risks through mandatory Boxed Warnings. These include the life-threatening risk of respiratory depression (slowed or stopped breathing) and the danger of profound sedation, coma, or death if the medicine is combined with CNS depressants (like benzodiazepines). These are documented as critical safety risks.

Q: Are there any specific safety warnings about operating machinery while using Bunondol?

Official product information includes a warning that Bunondol may impair the mental and physical abilities necessary for certain activities. This includes the ability to perform potentially hazardous tasks such as driving a vehicle or operating heavy machinery.

Q: What does the term 'high-risk medication' mean when applied to Bunondol?

This medication is classified as having a risk of addiction, abuse, and misuse, even when used as described by the prescriber. Due to these risks, regulatory bodies require mandatory warnings and specific precautions, often under risk evaluation programs, to ensure appropriate use.

Q: Does Bunondol have a warning about driving?

Official warnings include a specific warning regarding driving while using this medicine. The drug may cause effects like dizziness or somnolence that can impair the abilities required for operating a vehicle safely.

Q: How long after discontinuing use does Bunondol stay in a person’s body?

According to pharmacokinetic studies, the elimination half-life of the active ingredient is approximately 24 to 42 hours. This measured time frame is what determines how long the substance remains measurable in the body's system after the last dose is taken.

Q: Is Bunondol a controlled substance or scheduled medication?

Yes, the active ingredient in Bunondol, Buprenorphine, is officially classified as a Schedule III controlled substance in the United States and is similarly controlled in other jurisdictions. This classification reflects the drug's potential for abuse and physical dependence.

Q: Does official guidance mention taking Bunondol with grapefruit juice?

Official guidance details interactions with a class of substances called CYP3A4 inhibitors. These inhibitors can potentially increase the amount of Bunondol absorbed into the bloodstream. The active ingredient can be affected by substances that inhibit the CYP3A4 enzyme system, which includes grapefruit juice.

Q: What should a patient know if they accidentally miss a dose of Bunondol, as per the leaflet?

The Patient Information Leaflet typically provides guidance regarding a missed dose. It generally describes taking the missed dose as soon as possible. If it is close to the time of the next scheduled dose, the information generally describes skipping the missed dose and resuming the normal schedule.

Q: What kind of patient monitoring is typically recommended while using Bunondol?

Regulatory documents describe the need for monitoring, particularly during the initiation of therapy or following dose changes. Monitoring for signs of sedation, respiratory depression, and potential drug interactions is necessary to ensure safe use.

Q: Is Bunondol a type of anti-inflammatory drug?

Regulatory documents classify Bunondol as a partial opioid agonist and an analgesic because it primarily acts on opioid receptors in the central nervous system. The medicine is not classified as a nonsteroidal anti-inflammatory drug (NSAID).

Q: Why is Bunondol sometimes referred to by multiple different names?

This is common in medicines because Bunondol is a brand name for the active ingredient, which is called Buprenorphine. Regulatory agencies and registries list both the generic name and the associated brand names in official documentation.

Q: Does Bunondol affect heart rate or blood pressure?

Official adverse event reporting includes less common effects that relate to cardiovascular function. These effects may include orthostatic hypotension (a drop in blood pressure upon standing) and changes in heart rate (such as tachycardia or bradycardia).

How should Bunondol be stored and disposed of?

How to Store and Dispose of Bunondol?

Requirement Type	Official Regulatory Condition
Storage Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F), protected from freezing.
Environmental Protection	Store in the original, tightly closed container and protect from moisture and direct light.
Child Safety Mandate	Must be stored safely out of the sight and reach of children to prevent accidental, potentially fatal overdose.
Disposal Instructions	Unused or expired medication must be discarded immediately. The preferred methods are authorized Drug Take-Back programs or flushing down the toilet/sink, as specifically recommended by the FDA for buprenorphine products due to the high risk of harm if ingested.